Rigosertib demonstrates considerable efficacy and safety in the treatment of advanced/metastatic cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa

Research output: Contribution to journalAbstract (Journal)peer-review

Original languageEnglish
Pages (from-to)S50-S50
Number of pages1
JournalJOURNAL OF INVESTIGATIVE DERMATOLOGY
Volume144
Issue number8
Publication statusPublished - Aug 2024
EventAnnual Meeting of the Society-for-Investigative-Dermatology (SID) - Dallas
Duration: 15 May 202418 May 2024

Cite this